Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct:262:27-35.
doi: 10.1016/j.imlet.2023.08.005. Epub 2023 Sep 3.

Leveraging microRNAs for cellular therapy

Marko Hasiuk  1 , Marianne Dölz  1 , Romina Marone  1 , Lukas T Jeker  2
Affiliations
Free article

Leveraging microRNAs for cellular therapy

Marko Hasiuk et al. Immunol Lett. 2023 Oct.
Free article

Abstract

Owing to Karl Landsteiner's discovery of blood groups, blood transfusions became safe cellular therapies in the early 1900s. Since then, cellular therapy made great advances from transfusions with unmodified cells to today's commercially available chimeric antigen receptor (CAR) T cells requiring complex manufacturing. Modern cellular therapy products can be improved using basic knowledge of cell biology and molecular genetics. Emerging genome engineering tools are becoming ever more versatile and precise and thus catalyze rapid progress towards programmable therapeutic cells that compute input and respond with defined output. Despite a large body of literature describing important functions of non-coding RNAs including microRNAs (miRNAs), the vast majority of cell engineering efforts focuses on proteins. However, miRNAs form an important layer of posttranscriptional regulation of gene expression. Here, we highlight examples of how miRNAs can successfully be incorporated into engineered cellular therapies.

Keywords: Cell therapy; Non-coding RNA; Synthetic biology; T cell; miR-17∼92; microRNA.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Lukas T. Jeker reports financial support was provided by European Research Council (ERC) grant agreement No. 818806. Lukas T. Jeker reports a relationship with Cimeio Therapeutics AG that includes: board membership, consulting or advisory, equity or stocks, and funding grants. Lukas T. Jeker has patent pending to University of Basel. LTJ is a co-founder and board member of Cimeio Therapeutics AG (Cimeio) and owns equity in Cimeio. LTJ and MD are inventors on a patent application related to using miRNAs for cellular therapies.

Publication types

MeSH terms

LinkOut - more resources